Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
12 "Yang Li"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
Funded articles
More +
Original Articles
Pediatric cancer
Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study
Tingting Chen, Chenggong Zeng, Juan Wang, Feifei Sun, Junting Huang, Jia Zhu, Suying Lu, Ning Liao, Xiaohong Zhang, Zaisheng Chen, Xiuli Yuan, Zhen Yang, Haixia Guo, Liangchun Yang, Chuan Wen, Wenlin Zhang, Yang Li, Xuequn Luo, Zelin Wu, Lihua Yang, Riyang Liu, Mincui Zheng, Xiangling He, Xiaofei Sun, Zijun Zhen
Cancer Res Treat. 2024;56(4):1252-1261.   Published online May 28, 2024
DOI: https://doi.org/10.4143/crt.2024.104
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The risk stratification of pediatric anaplastic large cell lymphoma (ALCL) has not been standardized. In this study, new risk factors were included to establish a new risk stratification system for ALCL, and its feasibility in clinical practice was explored.
Materials and Methods
On the basis of the non-Hodgkin’s lymphoma Berlin–Frankfurt–Munster 95 (NHL-BFM-95) protocol, patients with minimal disseminated disease (MDD), high-risk tumor site (multiple bone, skin, liver, and lung involvement), and small cell/lymphohistiocytic (SC/LH) pathological subtype were enrolled in risk stratification. Patients were treated with a modified NHL-BFM-95 protocol combined with an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).
Results
A total of 136 patients were enrolled in this study. The median age was 8.8 years. The 3-year event-free survival (EFS) and overall survival of the entire cohort were 77.7% (95% confidence interval [CI], 69.0% to 83.9%) and 92.3% (95% CI, 86.1% to 95.8%), respectively. The 3-year EFS rates of low-risk group (R1), intermediate-risk group (R2), and high-risk group (R3) patients were 100%, 89.5% (95% CI, 76.5% to 95.5%), and 67.9% (95% CI, 55.4% to 77.6%), respectively. The prognosis of patients with MDD (+), stage IV cancer, SC/LH lymphoma, and high-risk sites was poor, and the 3-year EFS rates were 45.3% (95% CI, 68.6% to 19.0%), 65.7% (95% CI, 47.6% to 78.9%), 55.7% (95% CI, 26.2% to 77.5%), and 70.7% (95% CI, 48.6% to 84.6%), respectively. At the end of follow-up, one of the five patients who received maintenance therapy with VBL relapsed, and seven patients receiving anaplastic lymphoma kinase inhibitor maintenance therapy did not experience relapse.
Conclusion
This study has confirmed the poor prognostic of MDD (+), high-risk site and SC/LH, but patients with SC/LH lymphoma and MDD (+) at diagnosis still need to receive better treatment (ClinicalTrials.gov number, NCT03971305).
  • 2,088 View
  • 112 Download
Close layer
Genitourinary cancer
Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study
Hang An, Keyang Liu, Kokoro Shirai, Ryo Kawasaki, Akiko Tamakoshi, Hiroyasu Iso
Cancer Res Treat. 2024;56(2):616-623.   Published online October 6, 2023
DOI: https://doi.org/10.4143/crt.2023.962
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The association of physical activity with the risk of bladder cancer remains inconsistent among Asian populations. We aimed to examine the association in a large Japanese cohort.
Materials and Methods
In a population-based prospective cohort study, a total of 50,374 Japanese adults aged 40-79 years without a history of cancer or cardiovascular disease who had information on physical activity from self-administrated questionnaires were used for analysis. We performed Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident bladder cancer after adjusting for several potential confounders.
Results
During the median 17.5 years of follow-up, 153 incident bladder cancers (116 men and 37 women) were identified. After the multivariable adjustment, HRs (95% CI) of bladder cancer concerning those with recreational sports participation of 1-2 hr/wk, 3-4 hr/wk, and 5 hr/wk and more were 0.67 (0.38-1.20), 0.79 (0.36-1.74), and 0.28 (0.09-0.89), respectively (p for trend=0.017). Compared with mostly sitting at the workplace, occupational physical activity of standing and walking were associated with a lower risk of bladder cancer (HR, 0.53 [95% CI, 0.32 to 0.85]). Hours of daily walking were not associated with the risk. The lower risk of bladder cancer was more evident for recreational sports (HR, 0.33 [95% CI, 0.10 to 1.00]), and for occupational standing and walking activity at work (HR, 0.57 [95% CI, 0.33 to 0.98]) among men.
Conclusion
Recreational sports participation and occupational physical activity were inversely associated with the risk of bladder cancer among Japanese, especially in men.

Citations

Citations to this article as recorded by  
  • Physical Activity and Cancer Incidence and Mortality: Current Evidence and Biological Mechanisms
    Joanna Kruk, Basil Hassan Aboul-Enein, Marta Ewelina Gołębiewska, Ewa Duchnik, Urszula Czerniak, Mariola Marchlewicz
    Cancers.2025; 17(9): 1410.     CrossRef
  • 4,653 View
  • 186 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Gastrointestinal cancer
Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study
Yuting Li, Ehab S. Eshak, Renzhe Cui, Kokoro Shirai, Keyang Liu, Hiroyasu Iso, Satoyo Ikehara, Akiko Tamakoshi, Shigekazu Ukawa, JACC Study Group
Cancer Res Treat. 2021;53(2):497-505.   Published online October 27, 2020
DOI: https://doi.org/10.4143/crt.2020.327
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Sedentary behavior attributes to the increased risk of some cancers and all-cause mortality. The evidence is limited for the association between television (TV) viewing time, a major sedentary behavior, and risk of colorectal cancer death. We aimed to examine this association in Japanese population.
Materials and Methods
A prospective cohort study encompassed of 90,834 men and women aged 40-79 years with no prior history of colorectal cancer who completed a self-administered food frequency questionnaire, and provided their TV viewing information. The participants were followed-up from 1988-1990 to the end of 2009. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the Cox proportional hazard regression for risk of colorectal cancer mortality according to TV viewing time.
Results
During the median 19.1-year follow-up period, we documented 749 (385 men and 364 women) colorectal cancer deaths. The multivariable-adjusted HRs for mortality from colorectal cancer were 1.11 (0.88-1.41) for 1.5 to < 3 hr/day, 1.14 (0.91-1.42) for 3 to < 4.5 hr/day and 1.33 (1.02-1.73) for ≥ 4.5 hr/day in comparison to < 1.5 hr/day TV watching; p-trend=0.038, and that for 1-hour increment in TV viewing time was 1.06 (1.01-1.11). Moreover, the multivariable-adjusted HR (95%CI) of colon cancer for 1-hour increment in TV viewing time was 1.07 (1.02-1.13). Age, body mass index, and level of leisure-physical activity did not show significant effect modifications on the observed associations.
Conclusion
TV viewing time is associated with the increased risk of colorectal cancer mortality among Japanese population, more specifically colon rather than rectal cancer.

Citations

Citations to this article as recorded by  
  • The causal effects of leisure screen time on irritable bowel syndrome risk from a Mendelian randomization study
    Liesheng Lu, Changqin Liu, Kunpeng Liu, Chenzhang Shi, Zhongchen Liu, Xun Jiang, Feng Wang
    Scientific Reports.2023;[Epub]     CrossRef
  • Association of Physical Activity and Sedentary Behavior With the Risk of Colorectal Cancer
    Sanghyun An, Sungjin Park
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Sedentary behavior and cancer–an umbrella review and meta-analysis
    Rafael Hermelink, Michael F. Leitzmann, Georgios Markozannes, Kostas Tsilidis, Tobias Pukrop, Felix Berger, Hansjörg Baurecht, Carmen Jochem
    European Journal of Epidemiology.2022; 37(5): 447.     CrossRef
  • 7,973 View
  • 141 Download
  • 6 Web of Science
  • 3 Crossref
Close layer
Central nervous system
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
Lin Lin, Jinquan Cai, Zixiao Tan, Xiangqi Meng, Ruiyan Li, Yang Li, Chuanlu Jiang
Cancer Res Treat. 2021;53(2):367-377.   Published online October 13, 2020
DOI: https://doi.org/10.4143/crt.2020.506
AbstractAbstract PDFPubReaderePub
Purpose
Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate.
Materials and Methods
IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation.
Results
We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC50 of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV+propidium iodide–cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment.
Conclusion
These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.

Citations

Citations to this article as recorded by  
  • From pathology to therapy: A comprehensive review of ATRX mutation related molecular functions and disorders
    Fan Xu, Daohan Yu, Jiazheng Guo, Jingze Hu, Yunlei Zhao, Chuanlu Jiang, Xiangqi Meng, Jinquan Cai, Yan Zhao
    Mutation Research - Reviews in Mutation Research.2025; 795: 108537.     CrossRef
  • Impact of NQO1 dysregulation in CNS disorders
    Li Yuhan, Maryam Khaleghi Ghadiri, Ali Gorji
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells
    Alexandr N. Chernov, Alexandr V. Kim, Sofia S. Skliar, Evgeniy V. Fedorov, Anna N. Tsapieva, Tatiana A. Filatenkova, Aleksei L. Chutko, Marina V. Matsko, Elvira. S. Galimova, Olga V. Shamova
    Cancer Chemotherapy and Pharmacology.2024; 93(5): 455.     CrossRef
  • Factors related to tumor response rate from TCGA three omics data—variants, expression, methylation
    Hyung-Min Ahn, Insu Park, Chang Geun Kim, Young Kyung Ko, Jeong-An Gim
    Journal of Environmental Science and Health, Part C.2024; 42(3): 173.     CrossRef
  • Comparison of MRI Sequences to Predict IDH Mutation Status in Gliomas Using Radiomics-Based Machine Learning
    Dilek N. G. Kasap, Nabila Gala Nacul Mora, David A. Blömer, Burak Han Akkurt, Walter Leonhard Heindel, Manoj Mannil, Manfred Musigmann
    Biomedicines.2024; 12(4): 725.     CrossRef
  • Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity
    Kate M. Saville, Rasha Q. Al-Rahahleh, Aisha H. Siddiqui, Morgan E. Andrews, Wynand P. Roos, Christopher A. Koczor, Joel F. Andrews, Faisal Hayat, Marie E. Migaud, Robert W. Sobol
    DNA Repair.2024; 140: 103700.     CrossRef
  • Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
    Bruno Agustín Cesca, Matías Daniel Caverzan, María Julia Lamberti, Luis Exequiel Ibarra
    International Journal of Molecular Sciences.2024; 25(14): 7525.     CrossRef
  • Tricarboxylic Acid Cycle Relationships with Non-Metabolic Processes: A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance
    Enol Álvarez-González, Luisa María Sierra
    International Journal of Molecular Sciences.2024; 25(16): 9054.     CrossRef
  • IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
    Kristian A. Choate, Evan P. S. Pratt, Matthew J. Jennings, Robert J. Winn, Paul B. Mann
    Biology.2024; 13(11): 885.     CrossRef
  • The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)
    Lingjie Zhang, Tong Deng, Zhongqi Liufu, Xueyu Liu, Bingjie Chen, Zheng Hu, Chenli Liu, Miles E Tracy, Xuemei Lu, Hai-Jun Wen, Chung-I Wu
    eLife.2024;[Epub]     CrossRef
  • Oncometabolites as Regulators of DNA Damage Response and Repair
    Susan E. Gueble, Ranjit S. Bindra
    Seminars in Radiation Oncology.2022; 32(1): 82.     CrossRef
  • Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
    Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde, Julie Bolcaen
    Cancers.2022; 14(7): 1821.     CrossRef
  • Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide
    Erkin Ozgiray, Fatma Sogutlu, Cigir Biray Avci
    Medical Oncology.2022;[Epub]     CrossRef
  • From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
    Xueyuan Sun, Sevin Turcan
    Cells.2021; 10(5): 1225.     CrossRef
  • From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy
    Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona
    International Journal of Molecular Sciences.2021; 22(11): 5574.     CrossRef
  • The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)
    Weilu Kuang, Wuzhong Jiang, Yinyun Chen, Yifu Tian, Zhengzheng Liu
    Cancer Biology & Therapy.2021; 22(5-6): 392.     CrossRef
  • Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
    Hong-Chieh Tsai, Kuo-Chen Wei, Pin-Yuan Chen, Chiung-Yin Huang, Ko-Ting Chen, Ya-Jui Lin, Hsiao-Wei Cheng, Yi-Rou Chen, Hsiang-Tsui Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 10,580 View
  • 230 Download
  • 17 Crossref
Close layer
Gastrointestinal cancer
Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer
Lin Fang, Fei-Hu Yan, Chao Liu, Jing Chen, Dan Wang, Chun-Hui Zhang, Chang-Jie Lou, Jie Lian, Yang Yao, Bo-Jun Wang, Rui-Yang Li, Shu-Ling Han, Yi-Bing Bai, Jia-Ni Yang, Zhi-Wei Li, Yan-Qiao Zhang
Cancer Res Treat. 2021;53(1):131-139.   Published online August 24, 2020
DOI: https://doi.org/10.4143/crt.2020.330
AbstractAbstract PDFSupplementary MaterialPubReader
Purpose
Systemic inflammatory response is a critical factor that promotes the initiation and metastasis of malignancies including pancreatic cancer (PC). This study was designed to determine and compare the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and fibrinogen-to-albumin ratio (FAR) in resectable PC and locally advanced or metastatic PC.
Materials and Methods
Three hundred fifty-three patients with resectable PC and 807 patients with locally advan-ced or metastatic PC were recruited in this study. These patients were classified into a training set (n=758) and a validation set (n=402). Kaplan-Meier survival plots and Cox proportional hazards regression models were used to analyze prognosis.
Results
Overall survival (OS) was significantly better for patients with resectable PC with low preoperative PLR (p=0.048) and MLR (p=0.027). Low FAR, MLR, NLR (p < 0.001), and PLR (p=0.003) were significantly associated with decreased risk of death for locally advanced or metastatic PC patients. FAR (hazard ratio [HR], 1.522; 95% confidential interval [CI], 1.261 to 1.837; p < 0.001) and MLR (HR, 1.248; 95% CI, 1.017 to 1.532; p=0.034) were independent prognostic factors for locally advanced or metastatic PC.
Conclusion
The prognostic roles of FAR, MLR, NLR, and PLR in resectable PC and locally advanced or metastatic PC were different. FAR showed the most prognostic power in locally advanced or metastatic PC. Low FAR was positively correlated with OS in locally advanced or metastatic PC, which could be used to predict the prognosis.

Citations

Citations to this article as recorded by  
  • Diagnostic Value of Neutrophil-to-Lymphocyte Ratio (NLR) in Intrahepatic Cholestasis of Pregnancy
    Dandan Ji, Mingyan Sheng, Liuyan Zhang, Yonggui Han, Qi Jiang, Qiongxiao Ruan
    British Journal of Hospital Medicine.2025; 86(1): 1.     CrossRef
  • Prognostic value of perioperative NER levels combined with Ca199 in cholangiocarcinoma surgery
    Jie Chen, Zhaowei Sun, Jingyun Guo, Maobing Wang, Qinlei Wang, Menshou Chen, Bingyuan Zhang, Yanfeng Liu, Zelin Wang, Juan Feng, Yujie Feng
    Current Problems in Surgery.2025; 65: 101719.     CrossRef
  • The utilization of hypoalbuminemia as a prognostic metric in patients with spinal metastases: A scoping review
    Jessica Ryvlin, Namal Seneviratne, Ali Haider Bangash, C. Rory Goodwin, Michael H. Weber, Raphaële Charest-Morin, John H. Shin, Anne L. Versteeg, Mitchell S. Fourman, Saikiran G. Murthy, Yaroslav Gelfand, Reza Yassari, Rafael De la Garza Ramos
    Brain and Spine.2025; 5: 104223.     CrossRef
  • The Diagnostic and Prognostic Role of Inflammatory Markers, Including the New Cumulative Inflammatory Index (IIC) and Mean Corpuscular Volume/Lymphocyte (MCVL), in Colorectal Adenocarcinoma
    Robert-Emmanuel Șerban, Dragoș-Marian Popescu, Mihail-Virgil Boldeanu, Dan Nicolae Florescu, Mircea-Sebastian Șerbănescu, Vasile Șandru, Afrodita Panaitescu-Damian, Dragoș Forțofoiu, Rebecca-Cristiana Șerban, Florin-Liviu Gherghina, Cristin-Constantin Ver
    Cancers.2025; 17(6): 990.     CrossRef
  • Establishment of a nomogram based on Lasso Cox regression for albumin combined with systemic immune-inflammation index score to predict prognosis in advanced pancreatic carcinoma
    Min Xu, Yu Long, Peisheng Chen, Ang Li, Jian Xin, Yonghua Xu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Predictive value of the fibrinogen-to-albumin ratio for hemorrhagic transformation following intravenous thrombolysis in ischemic stroke: a retrospective propensity score-matched analysis
    Xiao-Yu Liu, Hui-Yang Jia, Gang Wang
    Frontiers in Neurology.2025;[Epub]     CrossRef
  • Fibrinogen/albumin ratio is associated with first-ever cardiovascular events in patients with peritoneal dialysis
    Qiqi Yan, Guiling Liu, Ruifeng Wang, Dandan Li, Deguang Wang
    Annals of Medicine.2025;[Epub]     CrossRef
  • Prognostic value of preoperative white blood cell to hemoglobin ratio and fibrinogen to albumin ratio in patients with colorectal cancer
    Kang Li, Jing Yan, Haifeng Zhang, Chunlei Lu, Weijia Wang, Mingxiao Guo, Xiaoming Zhang, Zhaoyong Zhang
    Medicine.2024; 103(3): e37031.     CrossRef
  • Prognostic value of the fibrinogen-to-albumin ratio (FAR) in patients with chronic heart failure across the different ejection fraction spectrum
    Sirui Yang, Jiangyuan Pi, Wenfang Ma, Wenyi Gu, Hongxing Zhang, Anyu Xu, Yanqing Liu, Tao Shi, Fazhi Yang, Lixing Chen
    Libyan Journal of Medicine.2024;[Epub]     CrossRef
  • Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), and Eosinophil-to-Lymphocyte Ratio (ELR) as Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
    Qian-Qian Liao, Yan-Ju Mo, Ke-Wei Zhu, Feng Gao, Bin Huang, Peng Chen, Feng-Tian Jing, Xuan Jiang, Hong-Zhen Xu, Yan-Feng Tang, Li-Wei Chu, Hai-Ling Huang, Wen-Li Wang, Fang-Ning Wei, Dan-Dan Huang, Bin-Jing Zhao, Jia Chen, Hao Zhang
    International Journal of Chronic Obstructive Pulmonary Disease.2024; Volume 19: 501.     CrossRef
  • Nomogram for Predicting Postoperative Pulmonary Metastasis in Hepatocellular Carcinoma Based on Inflammatory Markers
    Huanjie Zhou, Haiping Zheng, Ying Wang, Ming Lao, Hong Shu, Meifang Huang, Chao Ou
    Cancer Control.2024;[Epub]     CrossRef
  • Predictive value of serum albumin levels on cancer survival: a prospective cohort study
    Quan Tang, Xu Li, Chun-Rong Sun
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer
    Jing-Yao Ren, Da Wang, Li-Hui Zhu, Shuo Liu, Miao Yu, Hui Cai
    World Journal of Gastrointestinal Oncology.2024; 16(3): 732.     CrossRef
  • A High Fibrinogen-to-Albumin Ratio on Admission is Associated with Early Neurological Deterioration Following Intravenous Thrombolysis in Patients with Acute Ischemic Stroke
    Shifu Sun, Yongqing Cheng, Lei Li, Honghong Zhu, Changxia Liu, Yongjun Cao
    Journal of Inflammation Research.2024; Volume 17: 4151.     CrossRef
  • Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
    Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
    Cancer Medicine.2024;[Epub]     CrossRef
  • The prognostic role of lymphocyte-to-monocyte ratio in patients with resectable pancreatic cancer: a systematic review and meta-analysis
    Haipeng Li, Shang Peng, Ran An, Nana Du, Huan Wu, Xiangcheng Zhen, Yuanzhi Gao, Zhenghong Li, Jingting Min
    PeerJ.2024; 12: e17585.     CrossRef
  • Monocyte to high-density lipoprotein ratio based prognostic nomogram for patients following allogeneic vascular replacement pancreaticoduodenectomy
    Xiao-Wen Ye, Zu-Yu Wang, Yun-Xia Shao, Ying-Chun Tang, Xiong-Jun Dong, Ya-Ning Zhu
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer
    Lu Zhang, Yan-Ping Chen, Min Ji, Le-Qian Ying, Chun-Chun Huang, Jing-Yi Zhou, Lin Liu
    World Journal of Gastrointestinal Oncology.2024; 16(9): 3875.     CrossRef
  • Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection
    Shaofei Chang, Yiping Zou, Jing Huang, Zhifei Li, Yuexiang Liang, Song Gao
    World Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Prognostic value of peripheral blood fibrinogen-to-albumin ratio and neutrophil-to-lymphocyte ratio in patients with locally advanced or metastatic pancreatic cancer
    Hao Cheng
    American Journal of Translational Research.2024; 16(11): 7165.     CrossRef
  • Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma
    Shuai Xu, Xiu-Ping Zhang, Guo-Dong Zhao, Wen-Bo Zou, Zhi-Ming Zhao, Qu Liu, Ming-Gen Hu, Rong Liu
    Hepatobiliary & Pancreatic Diseases International.2023; 22(2): 160.     CrossRef
  • Association between fibrinogen-to-albumin ratio and hemorrhagic transformation after intravenous thrombolysis in ischemic stroke patients
    Miaomiao Yang, Lisha Tang, Shijia Bing, Xiangqi Tang
    Neurological Sciences.2023; 44(4): 1281.     CrossRef
  • Predictive impact of fibrinogen-to-albumin ratio (FAR) for left ventricular dysfunction in acute coronary syndrome: a cross-sectional study
    Xuan Wang, Yi Hu, Hao Luan, Chaodi Luo, Kamila·Kamili, Tingting Zheng, Gang Tian
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Fibrinogen-to-albumin ratio percentage: An independent predictor of disease severity and prognosis in anti-N-methyl-D-aspartate receptor encephalitis
    Juan Du, Yingzhe Shao, Yajun Song, Kaixin Wang, Xuan Yang, Yanfei Li, Yaobing Yao, Zhe Gong, Yanjie Jia
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer
    Yuanlong Gu, Qianjin Hua, Zhipeng Li, Xingli Zhang, Changjie Lou, Yangfen Zhang, Wei Wang, Peiyuan Cai, Juan Zhao
    BMC Cancer.2023;[Epub]     CrossRef
  • Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysis
    Junyan Kou, Jing Huang, Jun Li, Zhen Wu, Liwei Ni
    Clinical and Experimental Medicine.2023; 23(7): 3895.     CrossRef
  • Prognostic analysis of the plasma fibrinogen combined with neutrophil‐to‐lymphocyte ratio in patients with non–small cell lung cancer after radical resection
    Gao‐Xiang Wang, Zhi‐Ning Huang, Ying‐Quan Ye, Shan‐Ming Tao, Mei‐Qing Xu, Mei Zhang, Ming‐Ran Xie
    Thoracic Cancer.2023; 14(15): 1383.     CrossRef
  • Clinical features of patients with MOG-IgG associated disorders and analysis of the relationship between fibrinogen-to-albumin ratio and the severity at disease onset
    Yue Li, Sai Wang, Panpan Liu, Jinxiu Ma, Xinjing Liu, Jing Yuan
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Low albumin‐to‐fibrinogen ratio predicts adverse clinical outcomes after primary total joint arthroplasty: A retrospective observational investigation
    Jingjing Shang, Shijie Jiang, Jinhong Gong, Gongyin Zhao, Dan Su, Liangliang Wang
    International Wound Journal.2023; 20(9): 3690.     CrossRef
  • The modified lymphocyte C-reactive protein score is a promising indicator for predicting 3-year mortality in elderly patients with intertrochanteric fractures
    Zile He, Chuangxin Zhang, Mingzi Ran, Xin Deng, Zilin Wang, Yanhong Liu, Hao Li, Jingsheng Lou, Weidong Mi, Jiangbei Cao
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection
    Yu-Ting Jiang, Tian-Cheng Wang, Wei Zhang
    Journal of Inflammation Research.2023; Volume 16: 3479.     CrossRef
  • Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status
    Zhengfeng Zhang, Dazhen Wang, Jianji Zhang, Yuli Ruan, Lu Zhao, Liu Yang, Ze Liu, Lei Yang, Changjie Lou
    Cancer Immunology, Immunotherapy.2023; 72(11): 3635.     CrossRef
  • The predictive value of the preoperative albumin‐to‐fibrinogen ratio for postoperative hospital length of stay in liver cancer patients
    Fang Li, Yuetong Ren, Jiacheng Fan, Jin Zhou
    Cancer Medicine.2023; 12(20): 20321.     CrossRef
  • Inflammatory Markers Showed Significant Incremental Value for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients
    Xiao Wang, Wenjun Wang, Xixiang Lin, Xu Chen, Mingxiang Zhu, Hongli Xu, Kunlun He
    Life.2023; 13(10): 1990.     CrossRef
  • FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis
    Jili Xu, Hongmei Zhang, Nan Che, Hengjin Wang
    Clinical and Experimental Medicine.2023; 23(8): 4779.     CrossRef
  • Development and validation of a prognostic nomogram model incorporating routine laboratory biomarkers for preoperative patients with endometrial cancer
    Rong Cong, Mingyang Li, Wan Xu, Xiaoxin Ma, Shuhe Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer
    Liuqing Ye, Guoming Zhou, Lingling Zhou, Dongguo Wang, Shunqiang Xiong, Chibo Liu, Guobing Zhang
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Fibrinogen-to-Albumin Ratio and Long-Term Mortality in Coronary Artery Disease Patients with Different Glucose Metabolism Status
    Yun Xie, Xiayan Xu, Dongmei Wang, Yang Zhou, Yu Kang, Wenguang Lai, Hongyu Lu, Jin Liu, Shiqun Chen, Junyan Xu, Xiaoming Yan, Xiaoyu Huang, Yong Liu
    Reviews in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma
    Koji Kubota, Akira Shimizu, Yuji Soejima
    Annals of Surgical Oncology.2022; 29(2): 1449.     CrossRef
  • Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma
    Koji Kubota, Akira Shimizu, Tsuyoshi Notake, Hitoshi Masuo, Kiyotaka Hosoda, Koya Yasukawa, Hikaru Hayashi, Kentaro Umemura, Atsushi Kamachi, Takamune Goto, Hidenori Tomida, Shiori Yamazaki, Yuji Soejima
    Annals of Surgical Oncology.2022; 29(2): 1437.     CrossRef
  • Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting
    Nardeen Perko, Shaker A. Mousa
    Cancers.2022; 14(12): 2879.     CrossRef
  • A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study
    Xiu-Ping Zhang, Yuan-Xing Gao, Shuai Xu, Guo-Dong Zhao, Ming-Gen Hu, Xiang-Long Tan, Zhi-Ming Zhao, Rong Liu
    International Journal of Surgery.2022; 106: 106891.     CrossRef
  • Predictive Value of Fibrinogen to Albumin Ratio for the Multivessel-Coronary Chronic Total Occlusion
    婷 于
    Advances in Clinical Medicine.2022; 12(09): 8311.     CrossRef
  • Preoperative peripheral blood inflammatory markers especially the fibrinogen-to-lymphocyte ratio and novel FLR-N score predict the prognosis of patients with early-stage resectable extrahepatic cholangiocarcinoma
    Shijie Li, Xingli Zhang, Changjie Lou, Yuanlong Gu, Juan Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Fibrinogen-to-Albumin Ratio Predicts Postcontrast Acute Kidney Injury in Patients with Non-ST Elevation Acute Coronary Syndrome after Implantation of Drug-Eluting Stents
    Yong Qiao, Mingkang Li, Linqing Li, Chengchun Tang, Vijaya Anand
    Journal of the Renin-Angiotensin-Aldosterone System.2022;[Epub]     CrossRef
  • Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
    Xiuqiong Chen, Zhaona Li, Jing Zhou, Qianhui Wei, Xinyue Wang, Richeng Jiang
    PeerJ.2022; 10: e14566.     CrossRef
  • Diagnostic and Prognostic Value of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratios on Acute Pancreatitis Patients
    Hasan ERGENÇ, Zeynep ERTÜRK, Ahmet Tarık EMİNLER, Hakan CİNEMRE
    Online Türk Sağlık Bilimleri Dergisi.2022; 7(1): 80.     CrossRef
  • Prognostic value of albumin-fibrinogen ratio in subarachnoid hemorrhage patients
    Xuyang Liu, Zhiyuan Yu, Dingke Wen, Lu Ma, Chao You
    Medicine.2021; 100(17): e25764.     CrossRef
  • Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study
    Huayang Pang, Weihan Zhang, Xianwen Liang, Ziqi Zhang, Xiaolong Chen, Linyong Zhao, Kai Liu, Danil Galiullin, Kun Yang, Xinzu Chen, Jiankun Hu
    Advances in Therapy.2021; 38(9): 4917.     CrossRef
  • Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection
    Li-Peng Zhang, Hu Ren, Yong-Xing Du, Cheng-Feng Wang
    World Journal of Gastroenterology.2020; 26(46): 7382.     CrossRef
  • 10,203 View
  • 202 Download
  • 52 Web of Science
  • 50 Crossref
Close layer
A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
Chun Li, Zhi-Jun Wuxiao, Xiaoqin Chen, Guanjun Chen, Yue Lu, Zhongjun Xia, Yang Liang, Hua Wang
Cancer Res Treat. 2020;52(2):573-585.   Published online December 6, 2019
DOI: https://doi.org/10.4143/crt.2019.542
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined.
Materials and Methods
To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berlin–Frankfurt–Münster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. This retrospective study consecutively enrolled 207 adult LBL patients at two hospitals from 2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors.
Results
In the present study, most clinical characteristics were similar between the two treatment groups except for age and lactate dehydrogenase (LDH) level. Patients treated with modified NHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHL-BFM- 95 regimen produced better treatment outcomes than those with HyperCVAD/MA in patients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high Eastern Cooperative Oncology Group scores, and bone marrow involvement were independent risk factors in T-LBL. No patients interrupted treatment for severe adverse events.
Conclusion
The results suggested that the modified regimen is well-tolerated and can produce the promising outcomes in patients with T-LBL or patients < 40 years.

Citations

Citations to this article as recorded by  
  • Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai
    Fangfang Yu, Jiahua Niu, Jianmin Yang, Jian Hou, Siguo Hao, Aibin Liang, Hong Xiong, Qi Zhu, Ligen Liu, Jun Shi, Juan Du, Bobin Chen, Rong Wei, Wenli Zhao, Lihua Sun, Yunhua Hou, Rong Tao, Xianmin Song
    Bone Marrow Transplantation.2025; 60(3): 380.     CrossRef
  • Cutaneous Involvement in a Case of T-lymphoblastic Lymphoma: A Rare Presentation
    Priyanka Kowe, Madhusmita Sethy, Biswanath Behera, Pritinanda Mishra, Ashutosh Panigrahi
    Indian Dermatology Online Journal.2025; 16(2): 326.     CrossRef
  • The Efficacy of Pediatric‐Inspired Regimens vs. Hyper‐CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta‐Analysis
    Wenqing Su, Melisa Stricherz, Alison Martin, Jonathan Belsey, Eric Kemadjou, Daniel J. DeAngelo
    American Journal of Hematology.2025; 100(5): 847.     CrossRef
  • Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis
    Xiaodan Luo, Zhiping Fan, Runhui Zheng, Fen Huang, Na Xu, Pengfei Qin, Jingren Lin, Chunyan Wang, Huiqiang Huang, Huo Tan, Qifa Liu
    Blood Science.2025; 7(2): e00222.     CrossRef
  • Subcutaneous panniculitis‐like T‐cell lymphoma in a young girl presenting with periorbital edema and fever: A case report
    Seyed Mohamad Kazem Nourbakhsh, Mohammad Bahadoram, Farid Kosari, Mehrdad Jafari, Nahid Aslani, Shakiba Hassanzadeh
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma
    Qihua Zou, Shuyun Ma, Xiaopeng Tian, Qingqing Cai
    Blood Science.2022; 4(3): 155.     CrossRef
  • Total Body Irradiation–Based Conditioning Regimen Improved the Survival of Adult Patients With T-Cell Lymphoblastic Lymphoma After Allogeneic Peripheral Blood Stem Cell Transplantation
    Jiahua Niu, Zhixiao Chen, Jie Gao, Huiying Qiu, Liping Wan, Ying Wang, Wenwei Wang, Yin Tong, Chongmei Huang, Yu Cai, Xiaowei Xu, Kun Zhou, Ying Zhang, Xinxin Xia, Chang Shen, Yu Wei, Tingfeng Chen, Xianmin Song, Jun Yang
    Cell Transplantation.2022;[Epub]     CrossRef
  • Characteristics of growth disturbances in patients with intracranial germinomas of different origins
    Bo Li, Jiayi Wang, Jiongxian Yang, Yanong Li, Yanwei Liu, Shuai Liu, Xiaoguang Qiu
    Child's Nervous System.2021; 37(8): 2531.     CrossRef
  • Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma
    Haizhu Chen, Yan Qin, Jianliang Yang, Peng Liu, Changgong Zhang, Xiaohui He, Shengyu Zhou, Sheng Yang, Lin Gui, Liqiang Zhou, Yan Sun, Yuankai Shi
    Annals of Hematology.2020; 99(12): 2847.     CrossRef
  • 8,468 View
  • 168 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Television Viewing Time and Breast Cancer Incidence for Japanese Premenopausal and Postmenopausal Women: The JACC Study
Jinhong Cao, Ehab Salah Eshak, Keyang Liu, Isao Muraki, Renzhe Cui, Hiroyasu Iso, Akiko Tamakoshi, JACC Study Group
Cancer Res Treat. 2019;51(4):1509-1517.   Published online March 21, 2019
DOI: https://doi.org/10.4143/crt.2018.705
AbstractAbstract PDFPubReaderePub
Purpose
The evidence on effects of TV viewing time among premenopausal and postmenopausal women for breast cancer risk remains controversial and limited.
Materials and Methods
A prospective study encompassing 33,276 (17,568 premenopausal, and 15,708 postmenopausal) women aged 40-79 years in whom TV viewing time, menstrual, and reproductive histories were determined by a self-administered questionnaire. The follow-up was from 1988 to 2009 and hazard ratios (HRs) with 95% confidence intervals (CIs) of breast cancer incidence were calculated for longer TV viewing time in reference to shorter TV viewing time by Cox proportional hazard models.
Results
During 16.8-year median follow-up, we found positive associations between TV viewing time and breast cancer incidence with a borderline significant trend among total women and a significant trend among postmenopausal women. Among total women, the multivariable HRs (95% CIs) for risk of breast cancer in reference to < 1.5 hr/day of TV viewing time were 0.89 (0.59-1.34) for 1.5 to < 3.0 hr/day, 1.19 (0.82-1.74) for 3.0 to < 4.5 hr/day, and 1.45 (0.91-2.32) for ≥ 4.5 hr/day (p for trend=0.053) and among postmenopausal women, the corresponding risk estimates were 1.10 (0.42-2.88), 2.54 (1.11-5.80), and 2.37 (0.92-6.10) (p for trend=0.009), respectively.
Conclusion
Prolonged TV viewing time was associated with increased risk of breast cancer, especially among postmenopausal women.

Citations

Citations to this article as recorded by  
  • METTL3 regulates FAM83D m6A modification to accelerate tumorigenesis of triple-negative breast cancer via the Wnt/β-catenin pathway
    Xiaodong Yu, Yaxun Li, Fanshuang Kong, Qun Xu
    Toxicology in Vitro.2024; 95: 105746.     CrossRef
  • Risk Factors for Female Breast Cancer: A Population Cohort Study
    Yu-Chiao Wang, Ching-Hung Lin, Shih-Pei Huang, Mingchih Chen, Tian-Shyug Lee
    Cancers.2022; 14(3): 788.     CrossRef
  • Sedentary behavior and risk of breast cancer: a dose–response meta-analysis from prospective studies
    Feifei Chong, Yanli Wang, Mengmeng Song, Qiuyu Sun, Weihong Xie, Chunhua Song
    Breast Cancer.2021; 28(1): 48.     CrossRef
  • Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study
    Yuting Li, Ehab S. Eshak, Renzhe Cui, Kokoro Shirai, Keyang Liu, Hiroyasu Iso, Satoyo Ikehara, Akiko Tamakoshi, Shigekazu Ukawa
    Cancer Research and Treatment.2021; 53(2): 497.     CrossRef
  • Association of job category and occupational activity with breast cancer incidence in Japanese female workers: the JACC study
    Gita Nirmala Sari, Ehab Salah Eshak, Kokoro Shirai, Yoshihisa Fujino, Akiko Tamakoshi, Hiroyasu Iso
    BMC Public Health.2020;[Epub]     CrossRef
  • Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer
    Xiuming Zhai, Zhaowei Yang, Xiji Liu, Zihe Dong, Dandan Zhou
    PeerJ.2020; 8: e9975.     CrossRef
  • 7,847 View
  • 148 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013
Lu-Lu Zhang, Guo-Hong Li, Yi-Yang Li, Zhen-Yu Qi, Ai-Hua Lin, Ying Sun
Cancer Res Treat. 2019;51(3):982-991.   Published online October 11, 2018
DOI: https://doi.org/10.4143/crt.2018.298
AbstractAbstract PDFPubReaderePub
Purpose
The incidence, risk factors and survival impact of secondary primary malignancies (SPMs) among survivors of nasopharyngeal carcinoma (NPC) treated with definitive intensity-modulated radiation therapy (IMRT) with or without chemotherapy are poorly characterized.
Methods
and Materials Consecutive patients (n=6,377) from the big-data intelligence platform at Sun Yat-sen University Cancer Center, China (in a high-incidence area) with newly diagnosed non-metastatic pathologically proven non-keratinizing undifferentiated NPC treated with IMRT±chemotherapy between January 2003 and June 2013 were retrospectively analyzed. Cumulative incidence of SPMs was calculated using the Kaplan-Meier method. Cox proportional hazards model was used to identify potential risk factors for SPMs and assess whether SPMs affect overall survival.
Results
Of the 6,377 patients, 189 (3.0%) suffered SPMs (median follow-up, 62 months). One-, 2-, 3-, 4-, and 5-cumulative risks of SPMs were 0.4%, 0.9%, 1.6%, 2.2%, and 2.6%, respectively. Latency from start of IMRT to SPMs diagnosis was 37 months (range, 6 to 102 months). In patients with SPMs, 14.3% suffered SPMs within 1 year post-IMRT: 1-3 years, 38.1%; 3-5 years, 33.9%; and >5 years, 13.7%. Lung cancer was the most common SPM (50/6,377, 0.78%). Multivariate analysis demonstrated sex (male, 64% increase), age (≥50 years, 68% increase), and smoking history (41% increase) were significant risk factors for SPMs, and SPMs were associated with poorer overall survival.
Conclusion
This large cohort study confirms SPMs a dreadful complication for long-term survivors of NPC treated with IMRT. SPMs negatively impact overall survival in NPC. Close follow-up is recommended for older male survivors with a smoking history.

Citations

Citations to this article as recorded by  
  • Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
    Yuming Zheng, Fen Xue, Dan Ou, Xiaoshuang Niu, Chaosu Hu, Xiayun He
    Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
  • Age-specific characteristics of head and neck second primary malignancies in patients treated for nasopharyngeal carcinoma: a retrospective study
    Q. Jiang, T. Xu, M. Zeng, Y. He, Y. Cai, Z. Huang
    International Journal of Oral and Maxillofacial Surgery.2024; 53(1): 11.     CrossRef
  • The prevalence of gastroesophageal reflux disease and laryngopharyngeal reflux in patients with dysphagia after radiotherapy for nasopharyngeal carcinoma
    Peter K. M. Ku, Alexander C. Vlantis, Thomas S. C. Hui, Zenon W. C. Yeung, Ryan H. W. Cho, Marc H. K. Wong, Alex K. F. Lee, David C. M. Yeung, Simon Y. P. Chan, Becky Y. T. Chan, Wai‐tsz Chang, Florence Mok, Kam‐hung Wong, Jeffrey K. T. Wong, Victor Abdul
    Head & Neck.2024; 46(7): 1637.     CrossRef
  • Maxillary sinus anterior wall recurrence after intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Y Fang, L Wang, X Chen, C Cao
    International Journal of Radiation Research.2024; 22(3): 803.     CrossRef
  • Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR
    Yongfeng Piao, Caineng Cao, Yuanfan Xu, Shuang Huang, Feng Jiang, Ting Jin, Qifeng Jin, Yonghong Hua, Qiaoying Hu, Xiaozhong Chen
    European Archives of Oto-Rhino-Laryngology.2022; 279(1): 353.     CrossRef
  • Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma
    Fen Xue, Xiaoshuang Niu, Chaosu Hu, Xiayun He
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Racial and ethnic disparities in nasopharyngeal cancer with an emphasis among Asian Americans
    Qian Wang, Hui Xie, Yannan Li, Nicholas Theodoropoulos, Yaning Zhang, Changchuan Jiang, Chi Wen, Laura S. Rozek, Paolo Boffetta
    International Journal of Cancer.2022; 151(8): 1291.     CrossRef
  • Factors associated with the development of second primary tumours in head and neck cancer patients
    Inmaculada Salcedo‐Bellido, Pilar Requena, Rocío Mateos, Carmen Ortega‐Rico, Rocío Olmedo‐Requena, Macarena Lozano‐Lorca, Juan Pedro Arrebola, Rocío Barrios‐Rodríguez
    European Journal of Cancer Care.2022;[Epub]     CrossRef
  • Nasopharyngeal carcinoma: an evolving paradigm
    Kenneth C. W. Wong, Edwin P. Hui, Kwok-Wai Lo, Wai Kei Jacky Lam, David Johnson, Lili Li, Qian Tao, Kwan Chee Allen Chan, Ka-Fai To, Ann D. King, Brigette B. Y. Ma, Anthony T. C. Chan
    Nature Reviews Clinical Oncology.2021; 18(11): 679.     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
    Ling‐Long Tang, Yu‐Pei Chen, Chuan‐Ben Chen, Ming‐Yuan Chen, Nian‐Yong Chen, Xiao‐Zhong Chen, Xiao‐Jing Du, Wen‐Feng Fang, Mei Feng, Jin Gao, Fei Han, Xia He, Chao‐Su Hu, De‐sheng Hu, Guang‐Yuan Hu, Hao Jiang, Wei Jiang, Feng Jin, Jin‐Yi Lang, Jin‐Gao Li,
    Cancer Communications.2021; 41(11): 1195.     CrossRef
  • Radiation-induced second primary squamous cell carcinoma of the oral cavity after radiotherapy for nasopharyngeal carcinoma
    Chao Liu, Lieqiang Liao, Guoying Wu, Honghong Yan, Xiaoqi Chen, Chao Wang, Xiajing Zheng, Ziyi Zeng, Zheng Zhao, Di Wu, Xuekui Liu
    Oral Oncology.2020; 109: 104863.     CrossRef
  • Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG
    James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au
    Oral Oncology.2020; 111: 105012.     CrossRef
  • 7,272 View
  • 150 Download
  • 16 Web of Science
  • 12 Crossref
Close layer
Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis
Yang Li, Lin-Quan Tang, Li-Ting Liu, Shan-Shan Guo, Yu-Jing Liang, Xue-Song Sun, Qing-Nan Tang, Jin-Xin Bei, Jing Tan, Shuai Chen, Jun Ma, Chong Zhao, Qiu-Yan Chen, Hai-Qiang Mai
Cancer Res Treat. 2018;50(4):1304-1315.   Published online January 8, 2018
DOI: https://doi.org/10.4143/crt.2017.463
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC).
Materials and Methods
A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups.
Results
One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia.
Conclusion
This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.

Citations

Citations to this article as recorded by  
  • Nasopharyngeal Carcinoma in Children, Current Treatment Approach
    Tal Ben-Ami
    Journal of Pediatric Hematology/Oncology.2024; 46(3): 117.     CrossRef
  • Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study
    Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929.     CrossRef
  • Epidemiology and treatment of head and neck malignancies in the AYA generation
    Takahiro Asakage
    International Journal of Clinical Oncology.2022; 27(3): 465.     CrossRef
  • Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
    Yu-Jing Liang, Li-Ting Liu, Yang Li, Pan Wang, Mei-Juan Luo, Dong-Xiang Wen, Qiu-Yan Chen, Hai-Qiang Mai
    JAMA Network Open.2022; 5(3): e220173.     CrossRef
  • LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    British Journal of Cancer.2022; 127(7): 1239.     CrossRef
  • Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy
    Ziyi Zeng, Chen Chen, Lanlan Guo, Cheng Zhang, Lei Chen, Chuanping Yuan, Lixia Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study
    Ya-Nan Jin, Ji-Jin Yao, Ya-Fei You, Hui-Jiao Cao, Zi-Zi Li, Dan-Ling Dai, Wang-Jian Zhang, Tia Marks, Bei Zhang, Liang-Ping Xia
    Radiotherapy and Oncology.2021; 161: 83.     CrossRef
  • Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period
    Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Kübra Ozkaya, Rasim Meral, Inci Ayan, Musa Altun
    Pediatric Blood & Cancer.2021;[Epub]     CrossRef
  • Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
    Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai
    European Journal of Cancer.2021; 159: 133.     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • LHX2 Facilitates the Progression of Nasopharyngeal Carcinoma via Activation of the FGF1/FGFR Axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients
    Naoya Murakami, Taisuke Mori, Yuko Kubo, Seiichi Yoshimoto, Kimiteru Ito, Yoshitaka Honma, Takao Ueno, Kenya Kobayashi, Hiroyuki Okamoto, Narikazu Boku, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami
    Journal of Radiation Research.2020; 61(1): 161.     CrossRef
  • The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
    Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu
    BMC Cancer.2020;[Epub]     CrossRef
  • Update in pediatric nasopharyngeal undifferentiated carcinoma
    Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach
    The British Journal of Radiology.2019;[Epub]     CrossRef
  • 8,880 View
  • 211 Download
  • 19 Web of Science
  • 14 Crossref
Close layer
Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients
Lu-Lu Zhang, Yi-Yang Li, Jiang Hu, Guan-Qun Zhou, Lei Chen, Wen-Fei Li, Ai-Hua Lin, Jun Ma, Zhen-Yu Qi, Ying Sun
Cancer Res Treat. 2018;50(4):1084-1095.   Published online November 15, 2017
DOI: https://doi.org/10.4143/crt.2017.359
AbstractAbstract PDFPubReaderePub
Purpose
Local relapse-free survival (LRFS) differs widely among patients with T4 category nasopharyngeal carcinoma (NPC). We aimed to build a nomogram incorporating clinicopathological information to predict LRFS in T4 NPC after definitive intensity-modulated radiation therapy (IMRT).
Materials and Methods
Retrospective study of 415 Chinese patients with non-metastatic T4 NPC treated with definitive IMRT with or without chemotherapy at our cancer center between October 2009 and September 2013. The nomogram for LRFS at 3 and 5 years was generated based on multivariate Cox proportional hazards regression, and validated using bootstrap resampling, assessing discriminative performance using the concordance index (C-index) and determining calibration ability via calibration curves.
Results
Five-year LRFS was 88.8%. We identified and incorporated four independent prognostic factors for LRFS: ethmoid sinus invasion, primary gross tumor volume, age, and pretreatment body mass index. The C-index of the nomogram for local recurrence was 0.732 (95% confidence interval, 0.726 to 0.738), indicating excellent predictive accuracy. The calibration curve revealed excellent agreement between nomogram-predicted and observed LRFS probabilities. Risk subgroups based on total point score cutoff values enabled effective discrimination of LRFS.
Conclusion
This pretreatment nomogram enables clinicians to accurately predict LRFS in T4 NPC after definitive IMRT, and could help to facilitate personalized patient counselling and treatment strategies.

Citations

Citations to this article as recorded by  
  • Radiomics and Deep Learning in Nasopharyngeal Carcinoma: A Review
    Zipei Wang, Mengjie Fang, Jie Zhang, Linquan Tang, Lianzhen Zhong, Hailin Li, Runnan Cao, Xun Zhao, Shengyuan Liu, Ruofan Zhang, Xuebin Xie, Haiqiang Mai, Sufang Qiu, Jie Tian, Di Dong
    IEEE Reviews in Biomedical Engineering.2024; 17: 118.     CrossRef
  • Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma
    Huan Liang, Weilin Tan, Jie Wang, Mengdan Li, Hua Pang, Xiaohui Wang, Lu Yang, Xingguo Jing
    Annals of Nuclear Medicine.2024; 38(10): 802.     CrossRef
  • Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
    Qun Zhang, Zhen‐Wei Peng, Zhuo‐Sheng Gu, Yan Wang, Fang He, Wen‐Bin Zhao, Wei Luo, Yong‐Yu Mei
    Cancer Medicine.2023; 12(1): 223.     CrossRef
  • Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity‐modulated radiotherapy treatment of T4 nasopharyngeal carcinoma
    Yanyan Chen, Quxia Zhang, Tianzhu Lu, Cairong Hu, Jingfeng Zong, Yun Xu, Wei Zheng, Lisha Chen, Senan Lin, Sufang Qiu, Luying Xu, Jianji Pan, Qiaojuan Guo, Shaojun Lin
    Head & Neck.2023; 45(5): 1130.     CrossRef
  • Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma
    Bingxin Gu, Mingyuan Meng, Mingzhen Xu, David Dagan Feng, Lei Bi, Jinman Kim, Shaoli Song
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(13): 3996.     CrossRef
  • Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma
    Shan-Shan Guo, Yan-Zhou Chen, Li-Ting Liu, Rong-Ping Liu, Yu-Jing Liang, Dong-Xiang Wen, Jing Jin, Lin-Quan Tang, Hai-Qiang Mai, Qiu-Yan Chen
    BMC Cancer.2022;[Epub]     CrossRef
  • DeepMTS: Deep Multi-Task Learning for Survival Prediction in Patients With Advanced Nasopharyngeal Carcinoma Using Pretreatment PET/CT
    Mingyuan Meng, Bingxin Gu, Lei Bi, Shaoli Song, David Dagan Feng, Jinman Kim
    IEEE Journal of Biomedical and Health Informatics.2022; 26(9): 4497.     CrossRef
  • Development and Validation of Prognostic Nomograms Based on Gross Tumor Volume and Cervical Nodal Volume for Nasopharyngeal Carcinoma Patients With Concurrent Chemoradiotherapy
    Cui-Dai Zhang, Mei Li, Ying-Ji Hong, Ze-Man Cai, Kai-Chun Huang, Zhi-Xiong Lin, Zhi-Ning Yang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
    Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
    Cancer Research and Treatment.2021; 53(3): 657.     CrossRef
  • Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery
    Yang-Yu Huang, Lei-Lei Wu, Xuan Liu, Shen-Hua Liang, Guo-Wei Ma
    BMC Cancer.2021;[Epub]     CrossRef
  • Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
    Bingxin Gu, Jianping Zhang, Guang Ma, Shaoli Song, Liqun Shi, Yingjian Zhang, Zhongyi Yang
    BMC Cancer.2020;[Epub]     CrossRef

  • Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics


    Peiyun Long, Youya Zang, Huan Wang, Xiumei Liang, Xuekun Xie, Zhiwei Han, Dongyi Lin, Zongyu Wang, Shan Huang, Chuang Chen
    OncoTargets and Therapy.2020; Volume 13: 2093.     CrossRef
  • Impact of Paranasal Sinus Invasion on Oncologic and Dosimetric Outcomes in Nasopharyngeal Carcinoma Following Intensity-Modulated Radiation Therapy—Implications for Risk Stratification and Planning Optimization
    Xin Zhou, Xiayun He, Fen Xue, Xiaomin Ou, Chaosu Hu
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients
    Nicola Alessandro Iacovelli, Alessandro Cicchetti, Anna Cavallo, Salvatore Alfieri, Laura Locati, Eliana Ivaldi, Rossana Ingargiola, Domenico A. Romanello, Paolo Bossi, Stefano Cavalieri, Chiara Tenconi, Silvia Meroni, Giuseppina Calareso, Marco Guzzo, Ce
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma
    Lu-Lu Zhang, Fei Xu, Di Song, Meng-Yao Huang, Yong-Shi Huang, Qi-Ling Deng, Yi-Yang Li, Jian-Yong Shao
    JAMA Network Open.2020; 3(12): e2029882.     CrossRef
  • Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups
    En-Hong Zhuo, Wei-Jing Zhang, Hao-Jiang Li, Guo-Yi Zhang, Bing-Zhong Jing, Jian Zhou, Chun-Yan Cui, Ming-Yuan Chen, Ying Sun, Li-Zhi Liu, Hong-Min Cai
    European Radiology.2019; 29(10): 5590.     CrossRef
  • Impact of paranasal sinus invasion on advanced nasopharyngeal carcinoma treated with intensity‐modulated radiation therapy: the validity of advanced T stage of AJCC/UICC eighth edition staging system
    Ying Wang, Jie Zhao, Yajie Zhao, Zhen Yang, Mingjun Lei, Zhanzhan Li, Rui Wei, Dengming Chen, Yuxiang He, Liangfang Shen
    Cancer Medicine.2018; 7(7): 2826.     CrossRef
  • 8,989 View
  • 202 Download
  • 18 Web of Science
  • 17 Crossref
Close layer
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
Qiu-Yan Chen, Shao-Yan Guo, Lin-Quan Tang, Tong-Yu Lu, Bo-Lin Chen, Qi-Yu Zhong, Meng-Sha Zou, Qing-Nan Tang, Wen-Hui Chen, Shan-Shan Guo, Li-Ting Liu, Yang Li, Ling Guo, Hao-Yuan Mo, Rui Sun, Dong-Hua Luo, Chong Zhao, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Mu-Sheng Zeng, Hai-Qiang Mai
Cancer Res Treat. 2018;50(3):861-871.   Published online September 13, 2017
DOI: https://doi.org/10.4143/crt.2017.237
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors.
Materials and Methods
By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above.
Results
Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm3; EBV DNA 0 copy/mL, GTVtotal ≥ 30 cm3; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm3) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal ≥ 30 cm3). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant.
Conclusion
Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.

Citations

Citations to this article as recorded by  
  • A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
    Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
    Radiotherapy and Oncology.2025; 203: 110660.     CrossRef
  • Risk stratification of LA‐NPC during chemoradiotherapy based on clinical classification and TVRR
    Qianlong Tang, Chaorong Mei, Bei Huang, Rui Huang, Le Kang, Ailin Chen, Na lei, Pengcheng Deng, Shouyan Ying, Peng Zhang, Yuan Qin
    Cancer Medicine.2024;[Epub]     CrossRef
  • A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma
    Xue-Liang Fang, Lian-Zhen Zhong, Wei Jiang, Cheng-Long Huang, Yuan Lei, Si-Qi Tang, Qing-Jie Li, Li-Zhi Liu, Li Tian, Ying-Qin Li, Yu-Pei Chen, Li Lin, Rui Guo, Wen-Fei Li, Jie Tian, Na Liu, Di Dong, Jun Ma, Ling-Long Tang
    iScience.2024; 27(8): 110431.     CrossRef
  • Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma
    Zhong‐zheng Xiang, Tao He, Yuan‐yuan Zeng, Fang Liu, Bian‐fei Shao, Tian Yang, Jia‐chun Ma, Xi‐ran Wang, Si‐ting Yu, Lei Liu
    Cancer Medicine.2023; 12(2): 1102.     CrossRef
  • A prognostic nomogram incorporating tumor size and lymph node size for patients with nasopharyngeal carcinoma
    Qi Yi, Jiazuo Cai, Yunen Lin, Zimei Hu, Jie Lin, Zhong Huang, Wei Liu, Ronghui Zheng, YaWei Yuan, Chengcong Chen
    American Journal of Otolaryngology.2023; 44(2): 103717.     CrossRef
  • Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma
    Qian Chen, Liangfang Shen, Shan Li
    European Archives of Oto-Rhino-Laryngology.2023; 280(5): 2497.     CrossRef
  • High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
    Xiaotian Xu, Fangze Wei, Lin Xiao, Runye Wu, Baojun Wei, Shengkai Huang, Junlin Yi, Wei Cui
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • MRI-based deep learning model predicts distant metastasis and chemotherapy benefit in stage II nasopharyngeal carcinoma
    Yu-Jun Hu, Lin Zhang, You-Ping Xiao, Tian-Zhu Lu, Qiao-Juan Guo, Shao-Jun Lin, Lan Liu, Yun-Bin Chen, Zi-Lu Huang, Ya Liu, Yong Su, Li-Zhi Liu, Xiao-Chang Gong, Jian-Ji Pan, Jin-Gao Li, Yun-Fei Xia
    iScience.2023; 26(6): 106932.     CrossRef
  • The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas
    Julie Kjems, Katrin Elisabet Håkansson, Claus Andrup Kristensen, Jesper Grau Eriksen, Morten Horsholt Kristensen, Anne Ivalu Sander Holm, Jens Overgaard, Christian Rønn Hansen, Ruta Zukauskaite, Jørgen Johansen, Ivan Richter Vogelius, Jeppe Friborg
    Radiotherapy and Oncology.2023; 186: 109771.     CrossRef
  • The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma
    Gaoyuan Wang, Zhe Dong, Chenglong Huang, Xiaojing Du, Lin Chen, Kunpeng Li, Rui Guo, Linglong Tang, Jun Ma
    Oral Oncology.2023; 145: 106500.     CrossRef
  • Clinical Significance of Baseline Epstein–Barr Virus DNA for Recurrent or Metastatic Primary Pulmonary Lymphoepithelioma-Like Carcinoma
    Qihua Zou, Kongjia Luo, Liping Kang, Caiwen Huang, Jianliang Mai, Yongbin Lin, Ying Liang
    Future Oncology.2023; 19(37): 2481.     CrossRef
  • Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin
    Li Hua, Shaojun Chen, Mengzhuan Wei, Yongqi Shen, Jianxin Long, Zhan Lin, Yiliang Meng, Chengxian Guo, Haixin Huang, Xiaoning Tu, Min Yao
    Cancer Biotherapy and Radiopharmaceuticals.2022; 37(1): 2.     CrossRef
  • Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era
    Shan‐Shan Yang, Ya‐Jun Pang, Zhi‐Qiang Wang, Bao‐Yu Zhang, Zhi‐Qiao Liu, En‐Ni Chen, Pu‐Yun OuYang, Fang‐Yun Xie
    Cancer Medicine.2022; 11(4): 1109.     CrossRef
  • Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma
    Xiaoyu Li, Xingchen Peng, Sha Zhao, Hong Zhang, Yong Jiang, Fei Liu, Ping Ai
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma
    Huiyun Yang, Rongjun Zhang, Ruyun Zhang, Bin Zhang, Yuan Xie, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Wei Jiang
    Strahlentherapie und Onkologie.2022; 198(9): 828.     CrossRef
  • Survival among subgroups of patients with stage II nasopharyngeal carcinoma
    Shi-Ting Huang, Dan-Ke Su
    Scientific Reports.2022;[Epub]     CrossRef
  • Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers
    Santiago Cabezas-Camarero, Pedro Pérez-Segura
    Cancers.2022; 14(12): 2858.     CrossRef
  • Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
    Laura Keller, Yassine Belloum, Harriet Wikman, Klaus Pantel
    British Journal of Cancer.2021; 124(2): 345.     CrossRef
  • Treatment Deescalation Strategies for Nasopharyngeal Cancer
    Anna Lee, James C. H. Chow, Nancy Y. Lee
    JAMA Oncology.2021; 7(3): 445.     CrossRef
  • Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein–Barr virus DNA
    Zhi‐Gong Wei, Xiao‐Lin Hu, Yan He, Hui Guan, Jing‐Jing Wang, Ling He, Xiao‐Li Mu, Zhe‐Ran Liu, Rui‐Dan Li, Xing‐Chen Peng
    Head & Neck.2021; 43(5): 1465.     CrossRef
  • Accumulation of LOX-1+ PMN-MDSCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to epstein–barr virus and relate to tumor recurrence
    Xing Li, Jin-Long Li, Nan Jiang, Jie Chen, Zi-Ming Liang, Zhen-Lin Zhao, Yan-Fang Xing
    Aging.2021; 13(1): 437.     CrossRef
  • A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
    Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primož Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito
    European Journal of Cancer.2021; 153: 109.     CrossRef
  • Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load
    Yu-Ting Jiang, Kai-Hua Chen, Jie Yang, Zhong-Guo Liang, Song Qu, Ling Li, Xiao-Dong Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Metastasis of nasopharyngeal carcinoma: What we know and do not know
    Ling-Ling Guo, Hai-Yun Wang, Li-Sheng Zheng, Ming-Dian Wang, Yun Cao, Yang Li, Zhi-Jie Liu, Li-Xia Peng, Bi-Jun Huang, Jian-Yong Shao, Chao-Nan Qian
    Visualized Cancer Medicine.2021; 2: 4.     CrossRef
  • Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature
    Chi Leung Chiang, Qiaojuan Guo, Wai Tong Ng, Shaojun Lin, Tiffany Sze Wai Ma, Zhiyuan Xu, Youping Xiao, Jishi Li, Tianzhu Lu, Horace Cheuk Wai Choi, Wenqi Chen, Eric Sze Chun Chau, Peter Ho Yin Luk, Shao Hui Huang, Brian O’Sullivan, Jianji Pan, Anne Wing
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma
    Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam, Chi-Leung Chiang, Chun-Yin Edwin Wong, Ming-Chun Darren Poon, Macy Tong,
    Cancers.2021; 13(17): 4286.     CrossRef
  • The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma
    Xin-Bin Pan, Ling Li, Song Qu, Long Chen, Shi-Xiong Liang, Xiao-Dong Zhu
    Oral Oncology.2020; 101: 104520.     CrossRef
  • Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients
    Natalia Samolyk-Kogaczewska, Ewa Sierko, Dorota Dziemianczyk-Pakiela, Klaudia Beata Nowaszewska, Malgorzata Lukasik, Joanna Reszec
    Cancers.2020; 12(2): 511.     CrossRef
  • Prognostic efficacy of extensive invasion of primary tumor volume for T3-4 nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
    Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
    Oral Oncology.2020; 100: 104478.     CrossRef
  • Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up
    Xue-Song Sun, Xiao-Yun Li, Bei-Bei Xiao, Sai-Lan Liu, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
    Oral Oncology.2020; 100: 104490.     CrossRef
  • Metastatic disease in head & neck oncology
    Paolo Pisani, Mario Airoldi, Anastasia Allais, Paolo Aluffi Valletti, Mariapina Battista, Marco Benazzo, Roberto Briatore, Salvatore Cacciola, Salvatore Cocuzza, Andrea Colombo, Bice Conti, Alberto Costanzo, Laura della Vecchia, Nerina Denaro, Cesare Fant
    Acta Otorhinolaryngologica Italica.2020; 40(SUPPL. 1): S1.     CrossRef
  • BHRF1 Enhances EBV Mediated Nasopharyngeal Carcinoma Tumorigenesis through Modulating Mitophagy Associated with Mitochondrial Membrane Permeabilization Transition
    Shujie Song, Zhiying Jiang, David Ethan Spezia-Lindner, Ting Liang, Chang Xu, Haifeng Wang, Ye Tian, Yidong Bai
    Cells.2020; 9(5): 1158.     CrossRef
  • Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area
    E. Muraro, E. Vaccher, C. Furlan, E. Fratta, G. Fanetti, D. A. Fae’, D. Martorelli, M. Cangemi, J. Polesel, F. Navarria, C. Gobitti, E. Comaro, C. Scaini, C. Pratesi, S. Zanussi, V. Lupato, G. Grando, V. Giacomarra, S. Sulfaro, L. Barzan, R. Dolcetti, A.
    Pathology & Oncology Research.2020; 26(4): 2459.     CrossRef
  • Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein–Barr Virus–Positive Nasopharyngeal Carcinoma
    Bin Hu, Ming Sun, Zijin Wang, Yanping Zheng, Weifeng Cai, Helen Hsiao-Hsing Shi, Yanzhen Zhuang, Qin Lin
    Clinical Chemistry.2020; 66(9): 1219.     CrossRef
  • Molecular Prognostic Value of Circulating Epstein–Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia
    Xulin Xie, Yupei Ren, Kun Wang, Bin Yi
    Genetic Testing and Molecular Biomarkers.2019; 23(7): 448.     CrossRef
  • Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study
    Sha‐Sha He, Yan Wang, Yong Bao, Xiu‐Yu Cai, Xing‐Li Yang, Dan‐Ming Chen, Yong Chen, Li‐Xia Lu
    Cancer Medicine.2018; 7(4): 1110.     CrossRef
  • Impact of paranasal sinus invasion on advanced nasopharyngeal carcinoma treated with intensity‐modulated radiation therapy: the validity of advanced T stage of AJCC/UICC eighth edition staging system
    Ying Wang, Jie Zhao, Yajie Zhao, Zhen Yang, Mingjun Lei, Zhanzhan Li, Rui Wei, Dengming Chen, Yuxiang He, Liangfang Shen
    Cancer Medicine.2018; 7(7): 2826.     CrossRef
  • Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004‐2013
    S.‐J. Huang, Y.‐Y. Tang, H.‐M. Liu, G.‐X. Tan, X. Wang, H. Zhang, F. Yang, S. Yang
    Clinical Otolaryngology.2018; 43(5): 1209.     CrossRef
  • Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
    Liang Peng, Yi Yang, Rui Guo, Yan‐Ping Mao, Cheng Xu, Yu‐Pei Chen, Ying Sun, Jun Ma, Ling‐Long Tang
    Cancer Medicine.2018; 7(12): 5988.     CrossRef
  • 9,399 View
  • 295 Download
  • 39 Web of Science
  • 39 Crossref
Close layer
Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study
Qiu-Yan Chen, Qing-Nan Tang, Lin-Quan Tang, Wen-Hui Chen, Shan-Shan Guo, Li-Ting Liu, Chao-Feng Li, Yang Li, Yu-Jing Liang, Xue-Song Sun, Ling Guo, Hao-Yuan Mo, Rui Sun, Dong-Hua Luo, Yu-Ying Fan, Yan He, Ming-Yuan Chen, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Hai-Qiang Mai
Cancer Res Treat. 2018;50(3):701-711.   Published online July 14, 2017
DOI: https://doi.org/10.4143/crt.2017.180
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC.
Materials and Methods
In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS).
Results
The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the highSAA group (> 4.28 mg/L) versus the low-SAA (≤ 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP (≤ 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA ≥ 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors.
Conclusion
The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.

Citations

Citations to this article as recorded by  
  • Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
    Jiahui Li, Qianwen Liu, Huiying Qin
    Medicine.2024; 103(34): e39377.     CrossRef
  • Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
    Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
    Scientific Reports.2024;[Epub]     CrossRef
  • Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study
    Ying Lu, Haixin Huang, Hui Yang, Xiaohua Hu, Meilian Liu, Changjie Huang, Xianbin Feng, Xishan Chen, Zhou Jiang
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4327.     CrossRef
  • Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma
    Ying Lu, Zhou Jiang, Huan Lin, Hui Yang, Xishan Chen, Haixin Huang
    Future Oncology.2022; 18(22): 2441.     CrossRef
  • Long‐term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma
    Wanxia Li, Jing Chen, Bijun Liang, Zonghua Li, Junzheng Li, Xiaofei Yuan, Shuting Wu, Fangfang Zeng, Xinyu Peng, Yanfei Li, Juan Lu, Feipeng Zhao, Xiong Liu
    Cancer Medicine.2021; 10(3): 883.     CrossRef
  • A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
    Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primož Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito
    European Journal of Cancer.2021; 153: 109.     CrossRef
  • Prognostic value of Epstein–Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases
    Hongling Qu, Yuli Huang, Shufen Zhao, Yuanqing Zhou, Weibiao Lv
    European Archives of Oto-Rhino-Laryngology.2020; 277(1): 9.     CrossRef
  • The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S‐D) grade in patients with nasopharyngeal carcinoma
    Jianpei Li, Changchun Lai, Songguo Peng, Hao Chen, Lei Zhou, Yufeng Chen, Shulin Chen
    Clinical and Translational Medicine.2020;[Epub]     CrossRef
  • Utility of a Simple Scoring System in Differentiating Bacterial Infections in Cases of Fever of Unknown Origin
    Teng Xu, Li Wang, Shi Wu, Fenfen Zhou, Haihui Huang
    Clinical Infectious Diseases.2020; 71(Supplement): S409.     CrossRef
  • The prognostic value of serum amyloid A in solid tumors: a meta-analysis
    Hai-yingjie Lin, Guo-qiang Tan, Yan Liu, Shao-qiang Lin
    Cancer Cell International.2019;[Epub]     CrossRef
  • Molecular Prognostic Value of Circulating Epstein–Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia
    Xulin Xie, Yupei Ren, Kun Wang, Bin Yi
    Genetic Testing and Molecular Biomarkers.2019; 23(7): 448.     CrossRef
  • Rapid detection of quantum dot immune chromatography nasopharyngeal carcinoma EBNA1 antibody
    Jian He, Jing Xu, Ping Wu, Lingfeng Liao, Huatao Quan, Jing Kang, Yongquan Tian, Yaoyun Tang
    Oncology Letters.2018;[Epub]     CrossRef
  • 9,635 View
  • 268 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP